LoadingLoadingLoadingNo insider open-market trades in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (1)
D.E. Shaw
$30.7M
added
Sells/Trims (2)
Viking Global
$466.5M
sold
Qube Research
$52.3M
trimmed
No tracked top-trader positions in HCA as of Oct 24, 03:56 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 24, 2026
Financial period
Q2 2026
Earnings per share
$7.50 expected
Revenue
Company release
FY2026 guidance
$77.00B to $79.50B
No comparable estimate
Estimates as of Oct 23, 2026
EPS expected
$5.83 to $7.35
Revenue expected
21 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 24, 2026 | $7.59 / $7.50Yahoo Finance | +1.23% beat | $20.23B No estimate | Unavailable |
| Mar 31, 2026 | Apr 24, 2026 | $7.15 / $7.13Yahoo Finance | +0.29% in line | $19.11B No estimate | Unavailable |
| Dec 31, 2025 | Jan 27, 2026 | $8.01 / $7.48Yahoo Finance | +7.14% beat | $19.51B No estimate | Unavailable |
| Sep 30, 2025 | Oct 24, 2025 | $6.96 / $5.73Yahoo Finance | +21.55% beat | $19.16B No estimate | Unavailable |
| Jun 30, 2025 | Jul 25, 2025 | $6.84 / $6.32Alpha Vantage | +8.23% beat | $18.61B No estimate | Unavailable |
| Mar 31, 2025 | Apr 25, 2025 | $6.45 / $5.75Alpha Vantage | +12.17% beat | $18.32B No estimate | Unavailable |
| Dec 31, 2024 | Jan 24, 2025 | $6.22 / $6.14Alpha Vantage | +1.30% beat | $18.29B No estimate | Unavailable |
| Sep 30, 2024 | Oct 25, 2024 | $4.90 / $4.98Alpha Vantage | -1.61% miss | $17.49B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $19.16B | $19.51B | $19.11B | $20.23B |
| Cost of what it sold | $11.15B | $11.34B | $16.25B | $17.16B |
| Gross profit | $8.02B | $8.18B | $2.86B | $3.07B |
| What it spent | ||||
| Sales and admin | $7.86B | $8.36B | — | — |
| Other operating costs | -$2.81B | -$3.36B | $16.25B | $17.16B |
| Total operating expenses | $5.05B | $5.00B | $16.25B | $17.16B |
| What was left | ||||
| Operating profit | $2.96B | $3.18B | $2.86B | $3.07B |
| Interest on debt | $561.0M | $572.0M | $584.0M | $599.0M |
| Profit before tax | $2.42B | $2.67B | $2.29B | $2.49B |
| Tax | $515.0M | $509.0M | $430.0M | $564.0M |
| Net profit | $1.64B | $1.88B | $1.62B | $1.70B |
| EBITDA | $3.87B | $4.16B | $3.80B | $4.01B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
HCA Healthcare Q3 2026 Earnings Preview — October 27, Street Expects $6.63 EPS
Leans bearishOct 22ResMed (RMD) Projected to Release Earnings on Thursday
NeutralOct 22Closing the preeclampsia prevention gap with low-dose aspirin
BullishOct 22HCA Healthcare stock: TD Cowen lifts target to USD 460
NeutralOct 21HCA Healthcare Inc. stock underperforms Wednesday when compared to competitors
Leans bearishOct 21HCA Healthcare to Host Eighth Annual “Crush the Crisis” National Prescription Drug Take Back Day
BullishOct 21HCA Healthcare stock heads to October 27 earnings with USD 19.33 billion forecast
Leans bullishOct 21Raymond James sets USD 39.00 target for Acadia Healthcare stock
NeutralOct 20
